I spend most of my time on this site writing about the biochemistry of semaglutide in female physiology — the pharmacokinetic differences, the hormonal interactions, the side effect gender gap that nobody seems to want to address. But there’s a question I get more than any other, and it has nothing to do with GLP-1 receptor binding: where do people actually get this stuff?
So let’s talk about that. And let me be direct about my position before we go any further.
The Prescription Path Is the Right Path
Semaglutide is FDA-approved. It has extensive clinical trial data — including the sex-stratified data I’ve spent months analyzing on this site. The dosing protocols, while imperfect for women, are at least backed by pharmacokinetic modeling. The manufacturing is GMP-certified. The product is sterile, properly formulated, and consistent batch to batch.
If you can get a prescription, get a prescription. Full stop.
The challenge, as many of you have told me, is access. Insurance denials. $1,000+ out-of-pocket costs. Providers who won’t prescribe for weight management. The compounding pharmacy crackdown that eliminated affordable alternatives for millions of women who were finally getting treatment that worked.
Telehealth has genuinely expanded access for women who were falling through these cracks. Licensed providers, legitimate prescriptions, pharmacy-dispensed medication — but without the gatekeeping that kept so many women from treatment in the first place.
Explore Licensed Telehealth Options
If you’re considering semaglutide, start with a licensed telehealth provider who can evaluate your individual pharmacology — your weight, your hormonal status, your metabolic profile. A prescription through a legitimate provider means pharmaceutical-grade product, proper dosing guidance, and medical oversight for the side effects that disproportionately affect women.
The telehealth platform I recommend to readers of this site is Delilah. They pair you with a licensed prescriber who evaluates your metabolic profile, hormonal status, and medical history before prescribing anything. Not everyone gets approved, which is actually the point. If you want pharmaceutical-grade semaglutide with proper medical oversight, start here.
The Research Peptide Landscape: What Exists and Why It Matters
For those of you who follow the research side of this space — and many of my readers do, because understanding the science is kind of the point of this site — there’s a parallel market of research-grade peptides that exists outside the pharmaceutical supply chain. These are sold as research chemicals, not medications. They’re labeled “not for human consumption,” and I want to be explicit: that labeling exists for regulatory and safety reasons that matter.
But the market exists, and pretending otherwise doesn’t serve anyone. So here’s what the vendor landscape actually looks like in 2026, analyzed the way I’d analyze anything: with data, skepticism, and an emphasis on what the chemistry tells us.
How I Evaluate Vendors (The Biochemist’s Checklist)
When I look at a research peptide vendor, I’m asking five questions — the same questions I’d ask about any analytical chemistry supplier:
- Third-party COA availability: Does an independent lab (not the vendor’s own) verify identity, purity, and endotoxin levels? For semaglutide specifically, the 39-amino-acid chain means more opportunities for synthesis errors, truncations, and racemization. A COA from a lab like Janoshik that tests via HPLC and mass spectrometry is the minimum standard.
- Purity thresholds: Pharmaceutical semaglutide is ≥98% pure. Research-grade varies enormously. The impurities aren’t inert — they can include truncated peptide fragments, residual solvents, and bacterial endotoxins. For women, endotoxin contamination is particularly concerning because of estrogen’s role in amplifying inflammatory immune responses.
- Operating history: Vendors that have operated for years without FDA enforcement action aren’t necessarily safe, but vendors that appeared last month are a bigger unknown. Track record isn’t proof of quality, but it’s signal.
- Payment infrastructure: This sounds mundane, but it’s analytically useful. Vendors accepting credit cards have merchant accounts that require identity verification and create liability trails. Crypto-only vendors have less institutional accountability. Neither is inherently better or worse, but it tells you something about the vendor’s relationship with regulatory risk.
- Transparency about limitations: Does the vendor acknowledge what they are and aren’t? Vendors who blur the line between “research chemical supplier” and “pharmacy” are the ones I trust least.
2026 Vendor Comparison
| Vendor | Price Tier | Third-Party COA | Payment Methods | Operating Since | Regulatory Notes |
|---|---|---|---|---|---|
| Peptide Sciences | Premium | Yes | Cards | ~2012 | No public enforcement |
| Swiss Chems | Budget | Yes | Crypto | ~2016 | FDA warning letter (Dec 2024) |
| Biotech Peptides | Mid-range | Yes | Cards, crypto | ~2015 | No public enforcement |
| Panda Peptides | Budget | Yes (Janoshik) | Crypto, eCheck | ~2025 | No public enforcement |
| Evolve Peptides | Budget | Limited | Crypto | Jan 2025 | Too new for history |
| Pure Rawz | Mid-range | Yes | Crypto, Venmo | ~2015 | BBB complaints |
| Core Peptides | Mid-range | Varies | Crypto | ~2018 | No public enforcement |
A note on price tiers: I’m deliberately not listing exact prices because they change frequently and vary by product. “Premium” means consistently higher than market average. “Budget” means consistently lower. “Mid-range” is what it sounds like. Price alone tells you almost nothing about quality — some of the worst peptides I’ve seen COAs for were the most expensive.
Individual Vendor Notes
Peptide Sciences has the longest track record and charges accordingly. Their COAs are consistently available and they accept credit cards, which means they’ve maintained merchant processing relationships — not trivial in this industry. Whether the premium pricing reflects proportionally better product is debatable.
Swiss Chems received an FDA warning letter in December 2024 for marketing peptides with implied therapeutic claims. The warning letter doesn’t mean their products are impure — it means they crossed a regulatory line in their marketing. But it does mean the FDA is aware of them and watching.
Biotech Peptides occupies the middle of the market in both pricing and profile. They’ve operated since roughly 2015 without public regulatory action and accept multiple payment methods.
Panda Peptides is newer (2025) and uses Janoshik for third-party testing — which is actually the specific lab I’d choose if I were designing a testing protocol, given their HPLC and mass spec capabilities. Budget pricing with crypto and eCheck payment. Too new for a meaningful track record, but the testing transparency is a positive signal. Website: pandapeptides.com
Evolve Peptides launched in January 2025. Limited COA availability at this stage. Crypto-only payment. Too early to evaluate meaningfully — I’d want to see at least a year of consistent third-party testing before forming an opinion.
Pure Rawz has been around since roughly 2015 and accepts a wider range of payment methods including Venmo. They have BBB complaints on record, which is worth noting but also common for vendors in regulated-adjacent industries.
Core Peptides has operated since approximately 2018 with variable COA availability. “Variable” is a yellow flag for me — consistent third-party testing should be table stakes, not intermittent.
The Enforcement Reality
This industry has real regulatory risk, and pretending otherwise would be irresponsible. In 2024, Paradigm Peptides’ owner pleaded guilty to federal charges related to selling unapproved drugs. Swiss Chems received a formal FDA warning letter. The regulatory environment is tightening, not loosening.
For women researching this space: understand that research peptide vendors exist in a legal gray area. The products are sold for research use. The vendors who are most transparent about that distinction — rather than winking at it — are generally the ones operating most carefully.
My Recommendation
Get a prescription. Work with a licensed provider. Use pharmaceutical-grade semaglutide with proper medical oversight — especially given the sex-specific pharmacology I write about on this site. The dosing, the side effect management, the monitoring for gallbladder issues and pancreatitis — all of that is better with a physician in the loop.
If you’re researching the vendor landscape for academic or analytical purposes, the information above reflects my best assessment of the current market as of early 2026. It is not a recommendation to purchase, use, or self-administer any research chemical.
This page is for informational and research reference purposes only. Research peptides are sold strictly for in-vitro research and are not approved for human consumption. Nothing on this site constitutes medical advice, and no doctor-patient relationship is created by reading this content. Semaglutide for Women has no financial relationship with any research peptide vendor listed above. For our full disclosure policy, see our Affiliate & Vendor Disclosure. For health-related disclaimers, see our Medical Disclaimer.